If CTL019 is approved, the Swiss pharmaceutical giant plans to dole it out from about 30 preapproved sites, each trained in the multi-step process of harvesting
cells, handling the
product, and treating patients for the feverish and often life - threatening immune response that usually accompanies CAR -
T therapy.